European Medicines Agency (EMA) accepts marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma
The application is based on data from the phase II DREAMM-2 study which reported 31% overall response rate (ORR) with 2.5 mg/kg belantamab mafodotin in heavily pre-treated patients with multiple myeloma who were refractory to prior therapy.
Source:
Biospace Inc.
SPS commentary:
Belantamab mafodotin is a humanised IgG1 monoclonal antibody-drug conjugate consisting of an antibody that targets the B-cell maturation antigen, linked to monomethyl auristatin F, an anti-tubulin agent.